Search Within

Jonathan Eric Rosenberg

Formats
  1. Meeting Abstract (283)
  2. Journal Article (195)
  3. Review (18)
  4. Correspondence (10)
  5. Editorial (5)
  6. Guidelines (4)
  7. Book Section (2)
  8. Research Letter (2)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (520)
  2. Genitourinary Oncology Service (520)
  3. Solid Tumor Oncology Division (520)
  4. Department of Pathology and Laboratory Medicine (149)
  5. Surgery (140)
  6. Urology (137)

More Groups

People
  1. Dean Bajorin (204)
  2. Gopakumar Iyer (175)
  3. Hikmat Al-Ahmadie (134)
  4. Bernard Bochner (124)
  5. David Solit (114)
  6. Min Yuen Teo (75)

More People

Years
  1. 2025 (23)
  2. 2024 (36)
  3. 2023 (32)
  4. 2022 (36)
  5. 2021 (48)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (204)
  2. Annals of Oncology (42)
  3. European Urology (20)
  4. Clinical Genitourinary Cancer (18)
  5. Clinical Cancer Research (16)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (210)
  2. Oxford University Press (47)
  3. Elsevier Inc. (39)
  4. Elsevier Science, Inc. (36)
  5. Nature Publishing Group (36)
  6. American Association for Cancer Research (35)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma
    Journal Article

    Coleman, J. A.; Yip, W.; Wong, N. C.; Sjoberg, D. D.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; Donahue, T. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer
    Meeting Abstract

    Nagar, H.; Ballman, K. V.; Tagawa, S. T.; Tan, A.; Faltas, B. M.; Sheybani, A.; Baghaie, S.; Schwartz, L. H.; Kozono, D. E.; Bogart, J. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC)
    Meeting Abstract

    Katims, A. B.; Lenis, A. T.; Shah, R. H.; Chu, C. E.; Ratna, N.; Regazzi, A. M.; Pietzak, E. J.; Aggen, D. H.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Response Evaluation Criteria in Tumors of the Bladder (RECIT-Bladder) for future window of opportunity trials as a platform to accelerate drug development
    Meeting Abstract

    Gaffney, C.; Jiang, S.; de Jesus, M. R.; Chu, C. E.; Benfante, N.; Bajorin, D. F.; Donahue, T. F.; Rosenberg, J. E.; Iyer, G.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study
    Meeting Abstract

    Milowsky, M. I.; O'Donnell, P. H.; Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Moon, H. H.; Friedlander, T. W.; Mar, N.; McKay, R. R.; Srinivas, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K
    Meeting Abstract

    O'Donnell, P. H.; Rosenberg, J. E.; Hoimes, C. J.; Petrylak, D. P.; Milowsky, M. I.; McKay, R. R.; Srinivas, S.; Friedlander, T. W.; Ramamurthy, C.; Bilen, M. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC)
    Meeting Abstract

    Teo, M. Y.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Donahue, T. F.; Goh, A. C.; Cha, E. K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
    Journal Article

    Rudin, C. M.; Pandha, H. S.; Zibelman, M.; Akerley, W. L.; Harrington, K. J.; Day, D.; Hill, A. G.; O'Day, S. J.; Clay, T. D.; Wright, G. M.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer
    Journal Article

    Hoimes, C. J.; Flaig, T. W.; Milowsky, M. I.; Friedlander, T. W.; Bilen, M. A.; Gupta, S.; Srinivas, S.; Merchan, J. R.; McKay, R. R.; Petrylak, D. P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: A multicenter, randomized, phase II trial (BAYOU)
    Journal Article

    Rosenberg, J. E.; Park, S. H.; Kozlov, V.; Dao, T. V.; Castellano, D.; Li, J. R.; Mukherjee, S. D.; Howells, K.; Dry, H.; Lanasa, M. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save